Menactra Meningococcal Vaccine, Group A, C, Y & W-135, 16mcg + Diphtheria Toxoid 48mcg
C, Group A, Meningococcal Vaccine, Y & W-135
Meningococcal Vaccine, Group A, C, Y & W-135, prevents invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
Technical Specifications
| Drug Composition | C, Group A, Meningococcal Vaccine, Y & W-135 |
|---|---|
| Variant / Strength | '- |
| Dosage Form / Type | Injectables |
| Product Benefits | Prevention of Meningococcal disease |
| Packaging Type | Vial |
| Delivery Time | 7 - 15 Days, as per delivery location. |
| Country of Origin | Made in India |
| Export Destinations | USA, UK, UAE, Philippines, Thailand, Kenya, Nigeria, Germany, Canada, Mexico, and 65+ more countries |
| Export Route | Shipped via temperature-controlled international air courier with full customs documentation |
The Menactra Vaccine is utilized to prevent meningococcal disease, actively immunizing individuals against invasive Neisseria meningitidis serogroups A, C, Y, and W-135. Approved for those aged 9 months through 55 years, it should be administered by a healthcare professional and not self-administered. It is crucial to complete all vaccine doses for effectiveness. Individuals aged 15 to 55 at continued risk may receive a single booster dose after 4 to 6 years since the prior dose, with caution against intravenous, subcutaneous, or intradermal administration.
